Proto-oncogene receptor tyrosine kinase (RTK) ROS or ROS1, is a single-pass type I transmembrane glycoprotein that belongs to the insulin receptor (InsR) subfamily of the tyrosine protein kinase family. ROS1 comprises a 1832-aa large extracellular domain (ECD) with 9 fibronectin type-III motifs, a transmembrane region (TM), and a 465-aa intracellular kinase domain.  ROS1 is an orphan RTK that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. ROS1 may activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway.  ROS1 is expressed in brain and its expression is increased in primary gliomas and in a variety of tumor cell lines. A chromosomal aberration involving ROS1 is found in a glioblastoma multiforme sample. A SLC34A2-ROS1 chimeric protein produced in non-small cell lung cancer cells also retains a constitutive kinase activity. A third type of chimeric protein CD74-ROS1 was also identified in those cells.

Proto-oncogene receptor tyrosine kinase (RTK) ROS or ROS1, is a single-pass type I transmembrane glycoprotein that belongs to the insulin receptor (InsR) subfamily of the tyrosine protein kinase family. ROS1 comprises a 1832-aa large extracellular domain (ECD) with 9 fibronectin type-III motifs, a transmembrane region (TM), and a 465-aa intracellular kinase domain.  ROS1 is an orphan RTK that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. ROS1 may activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway.  ROS1 is expressed in brain and its expression is increased in primary gliomas and in a variety of tumor cell lines. A chromosomal aberration involving ROS1 is found in a glioblastoma multiforme sample. A SLC34A2-ROS1 chimeric protein produced in non-small cell lung cancer cells also retains a constitutive kinase activity. A third type of chimeric protein CD74-ROS1 was also identified in those cells.

 

Product Details

 

Gene Symbol: ROS1; ROS; MCF3; c-ros-1

 

NCBI Gene ID: 6098

 

Uniprot Entry: P08922

 

Construct Details: Full length human ROS1 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without an antibiotic selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. Multiple choices of a stable antibiotic selection marker are available.

 

Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter +/- a selection marker, see the vector map above)

  

Gene Insert Size: 7044 (bp)

 

Gene Insert Sequence:  

ATGAAGAACATTTACTGTCTTATTCCGAAGCTTGTCAATTTTGCAACTCTTGGCTGCCTATGGATTTCTG

TGGTGCAGTGTACAGTTTTAAATAGCTGCCTAAAGTCGTGTGTAACTAATCTGGGCCAGCAGCTTGACCT

TGGCACACCACATAATCTGAGTGAACCGTGTATCCAAGGATGTCACTTTTGGAACTCTGTAGATCAGAAA

AACTGTGCTTTAAAGTGTCGGGAGTCGTGTGAGGTTGGCTGTAGCAGCGCGGAAGGTGCATATGAAGAGG

AAGTACTGGAAAATGCAGACCTACCAACTGCTCCCTTTGCTTCTTCCATTGGAAGCCACAATATGACATT

ACGATGGAAATCTGCAAACTTCTCTGGAGTAAAATACATCATTCAGTGGAAATATGCACAACTTCTGGGA

AGCTGGACTTATACTAAGACTGTGTCCAGACCGTCCTATGTGGTCAAGCCCCTGCACCCCTTCACTGAGT

ACATTTTCCGAGTGGTTTGGATCTTCACAGCGCAGCTGCAGCTCTACTCCCCTCCAAGTCCCAGTTACAG

GACTCATCCTCATGGAGTTCCTGAAACTGCACCTTTGATTAGGAATATTGAGAGCTCAAGTCCCGACACT

GTGGAAGTCAGCTGGGATCCACCTCAATTCCCAGGTGGACCTATTTTGGGTTATAACTTAAGGCTGATCA

GCAAAAATCAAAAATTAGATGCAGGGACACAGAGAACCAGTTTCCAGTTTTACTCCACTTTACCAAATAC

TATCTACAGGTTTTCTATTGCAGCAGTAAATGAAGTTGGTGAGGGTCCAGAAGCAGAATCTAGTATTACC

ACTTCATCTTCAGCAGTTCAACAAGAGGAACAGTGGCTCTTTTTATCCAGAAAAACTTCTCTAAGAAAGA

GATCTTTAAAACATTTAGTAGATGAAGCACATTGCCTTCGGTTGGATGCTATATACCATAATATTACAGG

AATATCTGTTGATGTCCACCAGCAAATTGTTTATTTCTCTGAAGGAACTCTCATATGGGCGAAGAAGGCT

GCCAACATGTCTGATGTATCTGACCTGAGAATTTTTTACAGAGGTTCAGGATTAATTTCTTCTATCTCCA

TAGATTGGCTTTATCAAAGAATGTATTTCATCATGGATGAACTGGTATGTGTCTGTGATTTAGAGAACTG

CTCAAACATCGAGGAAATTACTCCACCCTCTATTAGTGCACCTCAAAAAATTGTGGCTGATTCATACAAT

GGGTATGTCTTTTACCTCCTGAGAGATGGCATTTATAGAGCAGACCTTCCTGTACCATCTGGCCGGTGTG

CAGAAGCTGTGCGTATTGTGGAGAGTTGCACGTTAAAGGACTTTGCAATCAAGCCACAAGCCAAGCGAAT

CATTTACTTCAATGACACTGCCCAAGTCTTCATGTCAACATTTCTGGATGGCTCTGCTTCCCATCTCATC

CTACCTCGCATCCCCTTTGCTGATGTGAAAAGTTTTGCTTGTGAAAACAATGACTTTCTTGTCACAGATG

GCAAGGTCATTTTCCAACAGGATGCTTTGTCTTTTAATGAATTCATCGTGGGATGTGACCTGAGTCACAT

AGAAGAATTTGGGTTTGGTAACTTGGTCATCTTTGGCTCATCCTCCCAGCTGCACCCTCTGCCAGGCCGC

CCGCAGGAGCTTTCGGTGCTGTTTGGCTCTCACCAGGCTCTTGTTCAATGGAAGCCTCCTGCCCTTGCCA

TAGGAGCCAATGTCATCCTGATCAGTGATATTATTGAACTCTTTGAATTAGGCCCTTCTGCCTGGCAGAA

CTGGACCTATGAGGTGAAAGTATCCACCCAAGACCCTCCTGAAGTCACTCATATTTTCTTGAACATAAGT

GGAACCATGCTGAATGTACCTGAGCTGCAGAGTGCTATGAAATACAAGGTTTCTGTGAGAGCAAGTTCTC

CAAAGAGGCCAGGCCCCTGGTCAGAGCCCTCAGTGGGTACTACCCTGGTGCCAGCTAGTGAACCACCATT

TATCATGGCTGTGAAAGAAGATGGGCTTTGGAGTAAACCATTAAATAGCTTTGGCCCAGGAGAGTTCTTA

TCCTCTGATATAGGAAATGTGTCAGACATGGATTGGTATAACAACAGCCTCTACTACAGTGACACGAAAG

GCGACGTTTTTGTGTGGCTGCTGAATGGGACGGATATCTCAGAGAATTATCACCTACCCAGCATTGCAGG

AGCAGGGGCTTTAGCTTTTGAGTGGCTGGGTCACTTTCTCTACTGGGCTGGAAAGACATATGTGATACAA

AGGCAGTCTGTGTTGACGGGACACACAGACATTGTTACCCACGTGAAGCTATTGGTGAATGACATGGTGG

TGGATTCAGTTGGTGGATATCTCTACTGGACCACACTCTATTCAGTGGAAAGCACCAGACTAAATGGGGA

AAGTTCCCTTGTACTACAGACACAGCCTTGGTTTTCTGGGAAAAAGGTAATTGCTCTAACTTTAGACCTC

AGTGATGGGCTCCTGTATTGGTTGGTTCAAGACAGTCAATGTATTCACCTGTACACAGCTGTTCTTCGGG

GACAGAGCACTGGGGATACCACCATCACAGAATTTGCAGCCTGGAGTACTTCTGAAATTTCCCAGAATGC

ACTGATGTACTATAGTGGTCGGCTGTTCTGGATCAATGGCTTTAGGATTATCACAACTCAAGAAATAGGT

CAGAAAACCAGTGTCTCTGTTTTGGAACCAGCCAGATTTAATCAGTTCACAATTATTCAGACATCCCTTA

AGCCCCTGCCAGGGAACTTTTCCTTTACCCCTAAGGTTATTCCAGATTCTGTTCAAGAGTCTTCATTTAG

GATTGAAGGAAATGCTTCAAGTTTTCAAATCCTGTGGAATGGTCCCCCTGCGGTAGACTGGGGTGTAGTT

TTCTACAGTGTAGAATTTAGTGCTCATTCTAAGTTCTTGGCTAGTGAACAACACTCTTTACCTGTATTTA

CTGTGGAAGGACTGGAACCTTATGCCTTATTTAATCTTTCTGTCACTCCTTATACCTACTGGGGAAAGGG

CCCCAAAACATCTCTGTCACTTCGAGCACCTGAAACAGTTCCATCAGCACCAGAGAACCCCAGAATATTT

ATATTACCAAGTGGAAAATGCTGCAACAAGAATGAAGTTGTGGTGGAATTTAGGTGGAACAAACCTAAGC

ATGAAAATGGGGTGTTAACAAAATTTGAAATTTTCTACAATATATCCAATCAAAGTATTACAAACAAAAC

ATGTGAAGACTGGATTGCTGTCAATGTCACTCCCTCAGTGATGTCTTTTCAACTTGAAGGCATGAGTCCC

AGATGCTTTATTGCCTTCCAGGTTAGGGCCTTTACATCTAAGGGGCCAGGACCATATGCTGACGTTGTAA

AGTCTACAACATCAGAAATCAACCCATTTCCTCACCTCATAACTCTTCTTGGTAACAAGATAGTTTTTTT

AGATATGGATCAAAATCAAGTTGTGTGGACGTTTTCAGCAGAAAGAGTTATCAGTGCCGTTTGCTACACA

GCTGATAATGAGATGGGATATTATGCTGAAGGGGACTCACTCTTTCTTCTGCACTTGCACAATCGCTCTA

GCTCTGAGCTTTTCCAAGATTCACTGGTTTTTGATATCACAGTTATTACAATTGACTGGATTTCAAGGCA

CCTCTACTTTGCACTGAAAGAATCACAAAATGGAATGCAAGTATTTGATGTTGATCTTGAACACAAGGTG

AAATATCCCAGAGAGGTGAAGATTCACAATAGGAATTCAACAATAATTTCTTTTTCTGTATATCCTCTTT

TAAGTCGCTTGTATTGGACAGAAGTTTCCAATTTTGGCTACCAGATGTTCTACTACAGTATTATCAGTCA

CACCTTGCACCGAATTCTGCAACCCACAGCTACAAACCAACAAAACAAAAGGAATCAATGTTCTTGTAAT

GTGACTGAATTTGAGTTAAGTGGAGCAATGGCTATTGATACCTCTAACCTAGAGAAACCATTGATATACT

TTGCCAAAGCACAAGAGATCTGGGCAATGGATCTGGAAGGCTGTCAGTGTTGGAGAGTTATCACAGTACC

TGCTATGCTCGCAGGAAAAACCCTTGTTAGCTTAACTGTGGATGGAGATCTTATATACTGGATCATCACA

GCAAAGGACAGCACACAGATTTATCAGGCAAAGAAAGGAAATGGGGCCATCGTTTCCCAGGTGAAGGCCC

TAAGGAGTAGGCATATCTTGGCTTACAGTTCAGTTATGCAGCCTTTTCCAGATAAAGCGTTTCTGTCTCT

AGCTTCAGACACTGTGGAACCAACTATACTTAATGCCACTAACACTAGCCTCACAATCAGATTACCTCTG

GCCAAGACAAACCTCACATGGTATGGCATCACCAGCCCTACTCCAACATACCTGGTTTATTATGCAGAAG

TTAATGACAGGAAAAACAGCTCTGACTTGAAATATAGAATTCTGGAATTTCAGGACAGTATAGCTCTTAT

TGAAGATTTACAACCATTTTCAACATACATGATACAGATAGCTGTAAAAAATTATTATTCAGATCCTTTG

GAACATTTACCACCAGGAAAAGAGATTTGGGGAAAAACTAAAAATGGAGTACCAGAGGCAGTGCAGCTCA

TTAATACAACTGTGCGGTCAGACACCAGCCTCATTATATCTTGGAGAGAATCTCACAAGCCAAATGGACC

TAAAGAATCAGTCCGTTATCAGTTGGCAATCTCACACCTGGCCCTAATTCCTGAAACTCCTCTAAGACAA

AGTGAATTTCCAAATGGAAGGCTCACTCTCCTTGTTACTAGACTGTCTGGTGGAAATATTTATGTGTTAA

AGGTTCTTGCCTGCCACTCTGAGGAAATGTGGTGTACAGAGAGTCATCCTGTCACTGTGGAAATGTTTAA

CACACCAGAGAAACCTTATTCCTTGGTTCCAGAGAACACTAGTTTGCAATTTAATTGGAAGGCTCCATTG

AATGTTAACCTCATCAGATTTTGGGTTGAGCTACAGAAGTGGAAATACAATGAGTTTTACCATGTTAAAA

CTTCATGCAGCCAAGGTCCTGCTTATGTCTGTAATATCACAAATCTACAACCTTATACTTCATATAATGT

CAGAGTAGTGGTGGTTTATAAGACGGGAGAAAATAGCACCTCACTTCCAGAAAGCTTTAAGACAAAAGCT

GGAGTCCCAAATAAACCAGGCATTCCCAAATTACTAGAAGGGAGTAAAAATTCAATACAGTGGGAGAAAG

CTGAAGATAATGGATGTAGAATTACATACTATATCCTTGAGATAAGAAAGAGCACTTCAAATAATTTACA

GAACCAGAATTTAAGGTGGAAGATGACATTTAATGGATCCTGCAGTAGTGTTTGCACATGGAAGTCCAAA

AACCTGAAAGGAATATTTCAGTTCAGAGTAGTAGCTGCAAATAATCTAGGGTTTGGTGAATATAGTGGAA

TCAGTGAGAATATTATATTAGTTGGAGATGATTTTTGGATACCAGAAACAAGTTTCATACTTACTATTAT

AGTTGGAATATTTCTGGTTGTTACAATCCCACTGACCTTTGTCTGGCATAGAAGATTAAAGAATCAAAAA

AGTGCCAAGGAAGGGGTGACAGTGCTTATAAACGAAGACAAAGAGTTGGCTGAGCTGCGAGGTCTGGCAG

CCGGAGTAGGCCTGGCTAATGCCTGCTATGCAATACATACTCTTCCAACCCAAGAGGAGATTGAAAATCT

TCCTGCCTTCCCTCGGGAAAAACTGACTCTGCGTCTCTTGCTGGGAAGTGGAGCCTTTGGAGAAGTGTAT

GAAGGAACAGCAGTGGACATCTTAGGAGTTGGAAGTGGAGAAATCAAAGTAGCAGTGAAGACTTTGAAGA

AGGGTTCCACAGACCAGGAGAAGATTGAATTCCTGAAGGAGGCACATCTGATGAGCAAATTTAATCATCC

CAACATTCTGAAGCAGCTTGGAGTTTGTCTGCTGAATGAACCCCAATACATTATCCTGGAACTGATGGAG

GGAGGAGACCTTCTTACTTATTTGCGTAAAGCCCGGATGGCAACGTTTTATGGTCCTTTACTCACCTTGG

TTGACCTTGTAGACCTGTGTGTAGATATTTCAAAAGGCTGTGTCTACTTGGAACGGATGCATTTCATTCA

CAGGGATCTGGCAGCTAGAAATTGCCTTGTTTCCGTGAAAGACTATACCAGTCCACGGATAGTGAAGATT

GGAGACTTTGGACTCGCCAGAGACATCTATAAAAATGATTACTATAGAAAGAGAGGGGAAGGCCTGCTCC

CAGTTCGGTGGATGGCTCCAGAAAGTTTGATGGATGGAATCTTCACTACTCAATCTGATGTATGGTCTTT

TGGAATTCTGATTTGGGAGATTTTAACTCTTGGTCATCAGCCTTATCCAGCTCATTCCAACCTTGATGTG

TTAAACTATGTGCAAACAGGAGGGAGACTGGAGCCACCAAGAAATTGTCCTGATGATCTGTGGAATTTAA

TGACCCAGTGCTGGGCTCAAGAACCCGACCAAAGACCTACTTTTCATAGAATTCAGGACCAACTTCAGTT

ATTCAGAAATTTTTTCTTAAATAGCATTTATAAGTCCAGAGATGAAGCAAACAACAGTGGAGTCATAAAT

GAAAGCTTTGAAGGTGAAGATGGCGATGTGATTTGTTTGAATTCAGATGACATTATGCCAGTTGCTTTAA

TGGAAACGAAGAACCGAGAAGGGTTAAACTATATGGTACTTGCTACAGAATGTGGCCAAGGTGAAGAAAA

GTCTGAGGGTCCTCTAGGCTCCCAGGAATCTGAATCTTGTGGTCTGAGGAAAGAAGAGAAGGAACCACAT

GCAGACAAAGATTTCTGCCAAGAAAAACAAGTGGCTTACTGCCCTTCTGGCAAGCCTGAAGGCCTGAACT

ATGCCTGTCTCACTCACAGTGGATATGGAGATGGGTCTGATTAA

 

Formulation: pre-packaged viral particles in the conditional medium (serum-free) from HEK293 cells (typical titer 10⁶ - 10⁷ IFU/ml)

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.